Mission Therapeutics

OverviewSuggest Edit

Mission Therapeutics is a company specializing in deubiquitylating enzyme drug discovery and development. It offers a platform for the discovery and development of small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The platform combines disease biology, screening tools, and chemistry, thereby generating a pipeline of highly potent and specific small-molecule drug candidates that have clinical and commercial potential.

TypePrivate
Founded2011
HQGreat Abington, GB
Websitemissiontherapeutics.com

Latest Updates

Employees (est.) (Sept 2021)39(+3%)
Cybersecurity ratingAMore

Key People/Management at Mission Therapeutics

Colin Goddard

Colin Goddard

Non-Executive Chairman
Anker Lundemose

Anker Lundemose

Chief Executive Officer, Director
Steve Jackson

Steve Jackson

Founder and Chairman of the Scientific Advisory Board
David Luther

David Luther

Chief Financial Officer
Graziano Seghezzi

Graziano Seghezzi

Director
Nick Edmunds

Nick Edmunds

Chief Technology Officer
Show more

Mission Therapeutics Office Locations

Mission Therapeutics has offices in Great Abington and Cambridge
Great Abington, GB (HQ)
Granta Park
Show all (2)

Mission Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2011

Mission Therapeutics total Funding

$142.9 m

Mission Therapeutics latest funding size

$15 m

Time since last funding

a year ago

Mission Therapeutics investors

Mission Therapeutics's latest funding round in July 2020 was reported to be $15 m. In total, Mission Therapeutics has raised $142.9 m
Show all financial metrics

Mission Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Mission Therapeutics Online and Social Media Presence

Embed Graph

Mission Therapeutics Blogs

Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

Mission receives $20 million milestone payment CAMBRIDGE, UK – 9 August 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB…

Mission Therapeutics to present at Solebury Trout, Venrock and Oppenheimer’s EU Summer Investor Tour

CAMBRIDGE, UK – 13 July 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that its CEO, Anker Lundemose, will be presenting at the 5th annual EU Investor Tour hosted by Solebury Trout, …

Mission Therapeutics Invited to Present at UBS Innovation Series: The Next Wave in Neurodegeneration

CAMBRIDGE, UK – 2 June 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer (CSO), will present at the upcoming Next Wave in Neurodegenerat…

Mission Therapeutics to Attend and Present at Bio€quity Europe Digital 2021

CAMBRIDGE, UK– 14 May 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced that management team members will be attending and presenting at Bio€quity Europe (17-19 May). Anker Lundemose, CEO…

Mission Therapeutics to Present at the Mitochondria-Targeted Drug Development Summit

CAMBRIDGE, UK– 26 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Mitochondria-Targeted Drug Development Di…

Mission Therapeutics to Participate in Upcoming SVB Leerink Biopharma Private Company Connect Event

CAMBRIDGE, UK– 22 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Eve…
Show more

Mission Therapeutics Frequently Asked Questions

  • When was Mission Therapeutics founded?

    Mission Therapeutics was founded in 2011.

  • Who are Mission Therapeutics key executives?

    Mission Therapeutics's key executives are Colin Goddard, Anker Lundemose and Steve Jackson.

  • How many employees does Mission Therapeutics have?

    Mission Therapeutics has 39 employees.

  • Who are Mission Therapeutics competitors?

    Competitors of Mission Therapeutics include Hisamitsu Pharmaceutical, Egis Pharmaceuticals and Maruishi Pharmaceutical.

  • Where is Mission Therapeutics headquarters?

    Mission Therapeutics headquarters is located at Granta Park, Great Abington.

  • Where are Mission Therapeutics offices?

    Mission Therapeutics has offices in Great Abington and Cambridge.

  • How many offices does Mission Therapeutics have?

    Mission Therapeutics has 2 offices.